Incyte R&D decreased by 15.6% to $515.90M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 18.0%, from $437.28M to $515.90M. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 8.9% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $343.51M | $334.95M | $472.83M | $353.37M | $347.20M | $384.01M | $501.36M | $406.64M | $400.75M | $375.71M | $444.49M | $429.26M | $1.14B | $573.17M | $466.03M | $437.28M | $494.92M | $506.58M | $611.37M | $515.90M |
| QoQ Change | — | -2.5% | +41.2% | -25.3% | -1.7% | +10.6% | +30.6% | -18.9% | -1.4% | -6.2% | +18.3% | -3.4% | +165.2% | -49.7% | -18.7% | -6.2% | +13.2% | +2.4% | +20.7% | -15.6% |
| YoY Change | — | — | — | — | +1.1% | +14.6% | +6.0% | +15.1% | +15.4% | -2.2% | -11.3% | +5.6% | +184.1% | +52.6% | +4.8% | +1.9% | -56.5% | -11.6% | +31.2% | +18.0% |